ImmunityBio (IBRX) plummeted 9.13% to $2.09 on Tuesday as investors await updates from the Piper Sandler 37th Annual Healthcare Conference. The company recently narrowed its net loss by 21.6% to $67.25 million, with revenues soaring 425% to $32.06 million thanks to strong sales of its NMIBC treatment, Anktiva.

Investors are eagerly anticipating ImmunityBio’s business updates and clinical pipeline outlook at the ongoing healthcare conference. While IBRX shows potential, some believe other AI stocks offer higher returns with limited downside risk. For more insights on AI stocks, check out the free report on the best short-term AI stock.

Read more at Yahoo Finance: ImmunityBio (IBRX) Slashes 9% on Lack of Leads